Synthesis of novel pyrimidine-based Schiff base complexes: Targeting Amyloid-β aggregation in Alzheimer’s disease
Makaleler > Tam Makale · 2024
Yazarlar: Sevil İRİŞLİ, Aslı Çakır, Salih GÜNNAZ
Bioorganic Chemistry, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Wos, 2024, cilt 154, ss 107999-107999
DOI: 10.1016/j.bioorg.2024.107999
Özet
A novel Schiff base with imine/amine donors, 5-((3,3-diphenylalilidene)amino)pyrimidine-4-amine (L), and its new Platinum(II) and Ruthenium(II) complexes (I and II) were synthesized and characterized using FT-IR, 1H NMR, 13C NMR, mass spectrometry and elemental analyses. The ability of these complexes to inhibit amyloid beta (Aβ1−42) aggregation was evaluated using the human neuroblastoma cell line (SH-SY5Y). The complexes effectively inhibited Aβ1−42 aggregation at a 1:1 M ratio. Both complexes increased cell viability up to 80 % at concentrations of 10 μM. At this concentration, the cell viability value found by Aβ1−42 aggregation is around 65 %. Aggregation kinetics were fluorometrically monitored using Thioflavin T. These findings were further supported by scanning electron microscopy and transmission electron microscopy. In addition, the interaction of the complexes with Aβ1−16 was investigated using MALDI-TOF/MS and 1H NMR spectroscopy. All findings showed that Aβ1−42 in both complexes is active in the inhibition of amyloid aggregation.